# CLAG Gleevec in Relapsed or Refractory Acute Myeloid Leukemia (AML)

> **NCT00955916** · PHASE2 · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 38 (actual)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** CLAG Regimen
- **DRUG:** Gleevec®

## Key facts

- **NCT ID:** NCT00955916
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08
- **Primary completion:** 2012-12
- **Final completion:** 2014-05
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2014-06-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00955916

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00955916, "CLAG Gleevec in Relapsed or Refractory Acute Myeloid Leukemia (AML)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00955916. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*